Themis Medicare Limited has informed the Exchange about Investor Presentation

TML/BSE/NSE/2025-26/36

13th November, 2025

Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001

Scrip Code – 530199

Dear Sir / Madam,

Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Symbol: THEMISMED

Subject: Investor Presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Company, with respect to Business Overview of Themis Medicare Limited (‘the Company’).

Further, a copy of the same is also available on the website of the Company, viz., https://www.themismedicare.com

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For THEMIS MEDICARE LIMITED

Pradeep Chandan Director – Legal, Compliance & Company Secretary

Themis Medicare Limited Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India *Tel.: 91-22-67607080*Fax: 91-22-67607070/ 28746621 Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: Regd. Off.: 0260-2431447/ 2430219 *E-mail: themis@themismedicare.com*Website: www.themismedicare.com

In every possibility lies an innate, latent power to change lives

Themis Medicare Ltd.

Result Update Presentation Q2 & H1 FY26

Disclaimer

This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

2

Table of Contents

Consolidated Financial Highlights

Company Overview

Way Ahead

3

Management Comment

Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said:

“The Company continued to face headwinds from disruption in a high margin major line of Business since the last two quarters. In this regard, regulators are currently investigating the matter and we expect a positive development on this by March 2026.

Despite the headwinds, our API business grew 31% year-on-year in the half-year period, while Trade business increased 4%. As part of our Hospital business, we aim to increase our focus on high margin brands and products.

Moving forward, we are striving to improve operational efficiency, cost optimization, field force productivity, and working capital management. Our R&D pipeline continues to be strong, and we will keep directing our efforts into creating differentiated products in critical therapeutic areas.

Consolidated revenue for the quarter was reported at ₹78 crore; muted performance in the formulations business hampered profitability. The Company remains resilient and we are cautiously optimistic based on our core competence and overall market opportunity.”

4

Consolidated Financial Highlights

Consolidated Quarterly Financial Highlights

Revenue (Rs. Cr.)*

117.0

EBITDA (Rs. Cr.)** / Margin (%)

93.8

97.6

71.7

78.0

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Q2 FY26

PAT (Rs. Cr.) / Margin (%)

12.2%

14.3

0.6%

0.5

-13.5%

-14.6%

-4.6%

14.6%

17.1

9.1%

8.5

-8.1%

-10.3%

-4.0%

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Q2 FY26

-5.8

-10.1

-3.1

EPS (Rs.)

1.55

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Q2 FY26

0.06

-3.6

-9.7

-14.2

*Revenue consists of Other Operating Revenue **EBITDA is excl. Other Income

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Q2 FY26 -0.39

-1.05

-1.54

6

Consolidated Quarterly Financial Highlights – Q2 FY26

Particulars (Rs. Cr.)

Net Revenue Cost of Material Consumed Purchase of SIT Changes in Inventory Employee Expenses Other Expenses Total Expenditure EBITDA EBITDA Margin Other Income Depreciation Interest / Finance Cost

Add: Share of P/L of Associates & JV

PBT Tax PAT PAT Margin% Basic EPS in Rs.

Q2 FY26 77.99 16.11 18.23 (10.19) 24.93 32.01 81.08 (3.09) (3.96%) 3.24 2.57 2.76

1.74

(3.45) 0.16 (3.62) (4.64%) (0.39)

Q2 FY25

117.01 21.06 18.12 2.46 24.38 33.87 99.88 17.13 14.6%

1.14 2.45 2.44

4.42 17.80

3.50 14.29 12.2%

1.55

Y-o-Y (%)

(33.3%)

(18.8%) (118.0%)

(125.3%)

(125.2%)

Q1 FY26 97.58 12.43 21.68 18.29 24.85 30.41 107.66 (10.08) (10.33%) 1.18 2.55 2.47

(0.14)

(14.06) 0.16 (14.22) (14.57%) (1.54)

• API

business

reported growth in the half year in with revenue

higher

share

• Headwinds

Formulations impacted top line

in business

• R&D investment at 3% of

revenue

7

Consolidated Financial Highlights – H1 FY26

Particulars (Rs. Cr.)

Net Revenue

Cost of Material Consumed

Purchase of SIT

Changes in Inventory

Employee Expenses

Other Expenses

Total Expenditure

EBITDA

EBITDA Margin

Other Income

Depreciation

Interest / Finance Cost

Add: Share of P/L of Associates & JV

PBT

Tax

PAT

PAT Margin%

EPS in Rs.

H1 FY26

175.57

28.54

39.90

8.10

49.78

62.42

188.74

(13.17)

(7.50%)

4.41

5.13

5.24

1.60

(17.52)

0.32

(17.84)

(10.16%)

(1.94)

H1 FY25

240.0

44.58

34.86

3.47

45.97

64.82

193.70

46.30

19.3%

2.10

4.86

4.80

10.40

49.14

10.16

38.98

16.2%

4.23

Y-o-Y (%)

(26.8%)

(2.6%)

(128.4%)

(145.8%)

(145.8%)

8

Consolidated Balance Sheet as on 30th Sep’25

Equity & Liabilities

As on 30th Sep’25

As on 31st Mar’25

Shareholders Funds

Share Capital

Other Equity

Non Controlling interest

Non Current Liabilities

Long Term Borrowing

Lease Liabilities

LT Provisions

Deferred Tax Liability(net)

Current Liabilities

Short term Borrowings

Lease Liabilities

Trade Payables

Total outstanding dues of micro and small

enterprises

Total outstanding dues of creditors other than micro and small enterprises

Other Financial Liabilities

Other Current Liabilities

Short term Provisions

Current Tax Liabilities (Net)

Total Equity & Liabilities

380.01

9.20

370.80

(0.00)

28.57

17.61

0.00

1.86

9.10

173.92

77.96 0.00

2.21

44.54

33.29

7.13

2.93

5.85

402.60

9.20

393.39

(0.00)

29.31

18.61

0.00

1.86

8.83

156.12

64.37

0.00

3.31

48.12

31.53

1.13

1.80

5.85

Assets

Non Current Assets

Plant, Property & Equipment

Capital Work In Progress

Right-of-use Assets

Intangible Assets

Investments

Financial Assets

Investments

Other Financial Assets

Deferred tax Assets (Net)

Other Non-Current Assets

Current Assets

Inventories

Financial Assets

Trade Receivables

Cash & Cash Equivalents

Bank balance other than above

Other Financial Assets

Other Current Assets

582.50

588.03

Total Assets

As on 30th Sep’25

As on 31st Mar’25

283.49

168.69

3.39

0.00

0.22

96.06

0.35

1.23

0.00

13.56

299.00

76.45

284.17

172.03

2.51

0.00

0.34

94.45

0.32

1.18

0.00

13.35

303.87

84.32

173.43

177.10

8.13

4.61

6.21

30.17

582.50

6.55

6.28

6.21

23.40

588.03

9

Company Overview

Snapshot of Company

Strategic focus To become Leader in Hospital Business in India with 4 growing divisions contributing 38.25% to revenue in FY24-25

3 State of art manufacturing facilities in India – 1 Formulations and 2 APIs (Synthetic + Biotech)

44+ Countries that we Export with Strong long- standing partnerships with global players for licensing (in & out).

Experienced professionals with proven

capabilities – 7 PhDs, 234 Masters and 1,339 Others

Strong Balance Sheet Total Debt to Equity at 0.21 in FY24-25

Rs. 1,129 Cr Market Cap (As on 12th November 2025)

12.10% EBITDA Margin (FY24-25)

Rs. 29.83 Cr PAT (FY24-25)

11

Strong Business Model

01

Hospital Business is major growth driver

03

Hospital Business

 Critical Care Division  Intensive Care Division  Institution Business  Exports

API Business

n

 API Legacy Business  New Product pipeline

supports hospital strategy and standalone global opportunities

n

02

Trade Business

n

 Pharma Division  Ortho Division  Gynecology Division  Strategy for growing through key brand focus in each division

Businesswise Revenue – H1 FY26

API, Co. Mkt & Others 24%

Trade 28%

Hospital 48%

Businesswise Revenue – FY24-25

Hospital 38%

API, Co. Mkt & Others 42%

Trade 20%

Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospitals/doctor’s coverage

12

Vertically Integrated State of Art Manufacturing Capabilities

Particulars

Location

Haridwar

Hyderabad

Vapi

Themis Medicare Ltd.

Artemis Biotech (Division of Themis Medicare Ltd.)

Themis Medicare Ltd.

Segment

Formulations

Synthetic APIs

Synthetic APIs

Capacity (per annum)

Tablets (Nos.) - 520 mn 9 mn Ointment (No. of Tubes) - 36 mn Ampoules (No. of Amp) - 12 mn Vials (No. of Vials) - 6 mn Pre-filled Syringes (Nos.)-

120 MT

Regulatory Approvals

EU GMP Certificate – Tablets & Gels

EU GMP

191 MT

GMP

Photos

13

Strong Research and Development Capabilities

Continued Investment in R&D (Rs. Cr.)

Business

API

Formulations

13.64

14.25

13.69

13.21

8.50

R&D

Analytical Lab Development

15

7

2

8

Product in a year with documentation

5 – 8

20-24

FY20-21

FY21-22

FY22-23

FY23-24

FY24-25

Products in work rolling

3 – 5

31

14

Way Ahead

Hospital Business Opportunity

n

Why Hospital Business Segment?  Growing market - Themis has strong foot in door through Critical

Care

 Market Highly Fragmented unlike West where 3-4 players control

90% market share

 Opportunities to grow segments within HB

High Entry Barriers  

Large Product Portfolio needed to service this segment Takes time to build relationship and reputation with key accounts

Opportunities Ahead  Focus on achieving Leadership position in India with Corporate Hospitals and Nursing Homes  With Expertise in Development of Complex Injectables - Company well placed to reap benefits

16

Our Aspirations

Strategy

 Focus on Hospital business  APIs to be developed - in- house consumption and commercial production

Vision & Position

 Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction

 Leadership in Anesthesia and Critical Care

New Target Markets

 Expansion in new RoW Markets in Phase I (0 to 3 years - CIS, Latin America, GCC)  Enter Regulated Markets in Phase II within

3 to 5 years – EU, USA

17

Thank You

It takes one word

to change

the world “POSSIBILITY”

For further information, please contact:

Mr. Pradeep Chandan

Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Website: www.themismedicare.com

Mr. Amit Sharma / Mr. Rahul Trivedi Tel: +91 9867726686 / 9833541841

Adfactors PR Pvt Ltd Email: amit.sharma@adfactorspr.com / rahul.Trivedi@adfactorspr.com Website : www.adfactorspr.com

18